Clinical Trial Detail

NCT ID NCT02417701
Title Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

lung squamous cell carcinoma

Therapies

Sapanisertib

Age Groups: senior adult

No variant requirements are available.